Abstract
The present report describes for the first time, the stability of recombinant adeno-associated virus serotype 2 (AAV2) human aromatic L-amino acid decarboxylase (hAADC) gene transfer after 3-year survival time in a non-human primate model of Parkinson's disease. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned monkeys were treated with six injections of 30 μl/site of AAV2-hAADC at a concentration of 2 × 1012 vg/ml into the caudate and putamen. Stereological analysis revealed a 46.6% increase in the total number of AAV2-hAADC-transduced cells in the striatum between 8 weeks and 3 years after gene transfer survival time. In the 8-week animals, the distribution of the AADC + cells was dispersed and heterogeneous, whereas in the 3-year animals it was widespread and homogenous. Confocal analysis demonstrated that approximately 85% of the AADC+ cells were neuronal nuclei immunoreactive.
Original language | English (US) |
---|---|
Pages (from-to) | 201-204 |
Number of pages | 4 |
Journal | NeuroReport |
Volume | 17 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2006 |
Externally published | Yes |
Keywords
- Gene therapy
- Long-term gene transfer
- Monkey MPTP
- Parkinson's disease
- Recombinant adeno-associated virus serotype 2
- Stereology
ASJC Scopus subject areas
- General Neuroscience